Journal Article Cites HemoVoid™ in Etiology Study of Cancer-related Anemia
By: Biotech Support Group
The citation is:
Kitao, Akihito, et al. "Band 3 ectopic expression in colorectal cancer induces an increase in erythrocyte membrane-bound IgG and may cause immune-related anemia (https://link.springer.com/
Autoimmune hemolytic anemia (AIHA) is a rare comorbidity in colorectal cancer (CRC) and has an unknown etiology. To better understand cancer-related anemia, the authors' investigated ectopic band 3 expression and erythrocyte membrane-bound IgG in a CRC cohort. To reduce the interference from Hemoglobin, the article states "Erythrocytes were lysed … and hemoglobin was depleted using HemoVoid (Biotech Support Group, NJ, USA, Cat. No. HVK-10)". The investigation concluded that anti-band 3 antibody was higher in the IgG fraction of CRC patients' compared to that of healthy controls, and that red cell membrane-bound IgG in patients with CRC, may be clinically associated to cancer-related anemia.
Whole Blood Compartments
"Through more efficient methods to measure the various blood components– red cells, white cells, platelets and plasma, we hope our products will contribute to understanding how these compartments cross-communicate. Those connections all play a role in normal homeostasis and in disease. This article illustrates how red cells react to IgG, and how this interaction plays a role in cancer-related anemia. For this purpose, I am pleased to see that our product HemoVoid™ was a necessary and efficient step to remove interferences from Hemoglobin in the Western blot analysis", states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.
For more information on HemoVoid™, visit:
For more information of all of our Hemoglobin removal products, visit:
About Biotech Support Group LLC
Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com (http://www.biotechsupportgroup.com/
Matthew Kuruc 732-274-2866, firstname.lastname@example.org
Biotech Support Group LLC